Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 15, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, March 14, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Chris Shibutani Maintained (AMLX) at Hold with Increased Target to $47 on, Mar 14th, 2023
Chris Shibutani of Goldman Sachs, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Hold with Increased Target from $41 to $47 on, Mar 14th, 2023.
Chris has made no other calls on AMLX in the last 4 months.
There is 1 other peer that has a rating on AMLX. Out of the 1 peers that are also analyzing AMLX, 0 agree with Chris's Rating of Hold.
This is the rating of the analyst that currently disagrees with Chris
- Geoff Meacham of "B of A Securities" Initiated at Strong Buy and Held Target at $50 on, Thursday, January 5th, 2023
